尤瑞克林治疗急性脑梗死的疗效及安全性  

Efficacy and safety of Urinary Kallidinogenase in treating patients with acute cerebral infarction

作　　者：李春树 于健 顾金萍 杨丽 刘琳 王之余 

机构地区：[1]Department of ICU,The second affiliated Hospital of Dalian Medical University

出　　处：《中华脑血管病杂志（电子版）》2009年第6期44-46,共3页Chinese Journal of Cerebrovascular Diseases(Electronic Edition)

摘　　要：目的观察尤瑞克林治疗急性脑梗死的疗效及安全性。方法 2007年1月至2009年2月我科收治的急性脑梗死患者14例,给予0.9%生理盐水100ml+尤瑞克林0.15PNA静脉滴注,每天1次,连续治疗7～14d。治疗期间针对性地给予抗血小板制剂(Aspirin100mg/d)以及其他常规治疗。结果 14例患者治疗7～14d后,平均NIHSS评分及ADL评分均较治疗前明显降低(P<0.05),临床疗效显著,总有效率达71.42%。结论尤瑞克林治疗急性重型缺血性脑卒中安全、有效,未发现明显副作用,值得临床推广使用。Objective The efficacy and safety of Urinary Kallidinogenase in treating patients with acute cerebral infarcti.on have been observed. Methods The therapeutic effect and adverse effect were analyzed in 14 cases of acute cerebral infarction who underwent intravenous injection of Urinary Kallidinogenase 0. 15 PNA qd in the ICU of the second affiliated Hospital of Dalian Medical University, from January 2007 to February 2009. The patients have been evaluated by NIHSS and ADL at 7-14 days after initiating the therapy. Results A significant improvement in NIHSS and ADL scores of these patients was noted. And 71.42% of them obtained satisfactory improvement. Conclusions Kallidinogenase injection showed a relatively confirmative effect on the improvement of cerebral functions in patients with acute cerebral infarction. The adverse effects were minimal. However, the exact efficacy needs further RCT clinical trials.

关 键 词：急性脑梗死患者 连续治疗 尤瑞克林 临床疗效 安全性 NIHSS评分 抗血小板制剂 缺血性脑卒中 

分 类 号：R743.3[医药卫生—神经病学与精神病学]